[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hair-lossbaldness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hair-lossbaldness":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100643276","study-to-evaluate-xtress-gummy-supplement-in-men-with-androgenic-alopecia-100643276",false,"NCT07637071","Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia","Pilot Study to Evaluate the Efficacy and Safety of Xtressé™ Gummy-Based Nutraceutical Supplement in Men With Androgenic Alopecia","Inclusion Criteria:\n\n* Males aged 18-65\n* Norwood III to IV, vertex focused\n* Fitzpatrick skin type I to VI\n* Ability and willingness to comply with study protocol\n\nExclusion Criteria:\n\n* Change in other hair treatments in 3 months prior to study enrollment.\n* Known uncontrolled health conditions.\n* History of hair or scalp disorders that could interfere with study results.\n* History of metabolic syndrome.","MALE","18 Years","65 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this study is to determine how safe and effective it is to improve hair growth using an active gummy treatment in men with androgenic alopecia.\n\nThe main aims of this trial are:\n\n1. To confirm using photographic analysis, changes in the quality, volume, and thickness of hair.\n2. To gauge patient satisfaction with hair changes and application process.\n3. Monitor and report any adverse events associated with the daily intake of Xtressé\n\nParticipants who qualify will complete 3 visits after voluntary consent has been given. Participants will be given a 90-day supply of the gummies at visits 1 and 2 to cover the 6-month study period. Photographs and scalp analysis will be performed at each visit to measure changes in hair volume, thickness, and growth.",[27,28,29],"Androgenic Alopecia","Hair Loss\u002FBaldness","Hair Thinning","NOT_YET_RECRUITING","2026-06-08",{"date":33,"type":34},"2026-06-10","ACTUAL",{"date":36,"type":21},"2026-06-22",{"date":38,"type":21},"2027-03",{"name":40,"class":41},"Restore Biologics Holdings, Inc. dba Xtressé","INDUSTRY",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":55,"conditions":56,"keywords":63,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":5},"100582895","phase-1-autologous-adipose-cells-therapy-100582895","NCT06869252","Autologous Adipose Cells Therapy","Inclusion Criteria:\n\n1. Outpatients who express interest in skin rejuvenation, and\u002For who are experiencing skin conditions, such as winkles, fine lines, loss of skin elasticity, skin pigmentation, scarring.\n2. Outpatients who are experiencing hair loss or hair thinning\n3. Provision of signed and dated informed consent form\n4. Clearly stated willingness to comply with all the procedures of the study and availability of the study\n5. Female and Male aged between 21 to 80 years old 6 Medical clearance by family doctor\n\nExclusion Criteria:\n\n1. Pregnancy or lactation\n2. Known allergic reaction to components of cell culture media\n3. Chronic disease , e.g. cardiovascular disease, diabetes, chronic kidney disease, seizures\n4. Chronic infections, e.g. skin fungi infection, psoriasis\n5. Chronic wound healing\n6. Currently taking hormone therapy\n7. History of cancers and active cancers\n8. Viral infection, e.g. HIV, hepatitis B, influenza, coronaviruses.","ALL","21 Years","80 Years",{"count":20,"type":21},[53,54],"PHASE1","PHASE2","Autologous Adipose Cell Therapy is a series of process designated to address the demerits of the traditional autologous fat grafting and dermal fillers, while enhancing the versatility and aesthetic outcomes. In this study, the goal is to evaluate the safety and efficacy of Autologous Adipose cell Therapy for skin rejuvenation and hair improvement in human application.",[28,57,58,59,60,29,61,62],"Wrinkle Appearance","Volume","Fine Lines","Skin Elasticity","Skin Pigmentation","Skin Texture",[64,65],"Adipose Cells","Adipocytes","RECRUITING","2025-05-30",{"date":69,"type":34},"2025-05-31",{"date":71,"type":21},"2025-08-01",{"date":73,"type":21},"2026-02-01",{"name":75,"class":41},"CERM INC."]